Conference item
Vedolizumab in Pediatric inflammatory bowel diseases: a retrospective multi-center experience from the paediatric IBD Porto group of ESPGHAN
- Abstract:
- Vedolizumab (VDZ) has proven as an effective medication in adult Inflammatory Bowel Disease (IBD). There has been increased off-label use of VDZ also in children but with very limited published experience. Therefore we aimed to describe the short-term effectiveness and safety of VDZ in children with IBD in the largest pediatric cohort to date.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 73.9KB, Terms of use)
-
- Publisher copy:
- 10.1093/ecco-jcc/jjx002.539
Authors
- Publisher:
- Oxford University Press
- Host title:
- Journal of Crohn's and Colitis
- Journal:
- 12th Congress of the European Crohn's and Colitis Organisation (ECCO 2017) More from this journal
- Volume:
- 11
- Issue:
- suppl_1
- Pages:
- S287-S288
- Publication date:
- 2017-01-26
- Acceptance date:
- 2016-12-23
- Event location:
- England
- DOI:
- EISSN:
-
1876-4479
- ISSN:
-
1873-9946
- Language:
-
English
- Keywords:
- Pubs id:
-
pubs:679138
- UUID:
-
uuid:15e15ff5-ca9e-45b8-8610-f6312930f7da
- Local pid:
-
pubs:679138
- Source identifiers:
-
679138
- Deposit date:
-
2018-10-15
Terms of use
- Copyright holder:
- European Crohn’s and Colitis Organisation
- Copyright date:
- 2017
- Notes:
- © 2017 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. This is the accepted manuscript version of the abstract. The final version is available online from Oxford University Press at: https://doi.org/10.1093/ecco-jcc/jjx002.539 This abstract was presented at the 12th Congress of the European Crohn's and Colitis Organisation (ECCO 2017)
If you are the owner of this record, you can report an update to it here: Report update to this record